Medicinal – Page 144

ESCMID-EFISG Survey on Diagnostic and Therapeutic Capacity for Invasive Fungal Infections in Belgium, the Netherlands, and Luxembourg: A Focus on High Azole Resistance

mycolabadmin

This survey examined how well hospitals in Belgium, the Netherlands, and Luxembourg can diagnose and treat serious fungal infections, especially in patients whose immune systems are weakened. The researchers found that while most hospitals have good access to testing and antifungal medications, some important tests are still missing, and many hospitals send samples to other facilities for testing, which can delay treatment. Since this region has unusually high rates of fungal infections that resist common antifungal drugs, improving access to advanced diagnostic tests is crucial for patient survival.

Insights into microbiome-triterpenoid correlation in Poria cocos via comparative analysis of sclerotial and soil microenvironments

mycolabadmin

This study explores how the medicinal mushroom Poria cocos creates its own special microbial environment inside its sclerotium (the part used in medicine). Researchers found that the mushroom selectively enriches certain bacteria and fungi while maintaining lower overall microbial diversity compared to surrounding soil. The study reveals that specific microbes like Burkholderia and Scytalidium are positively associated with the production of pachymic acid, the mushroom’s key medicinal compound with anti-tumor and anti-inflammatory properties.

Phylogenetic Analysis of Trichoderma Species Associated with Green Mold Disease on Mushrooms and Two New Pathogens on Ganoderma sichuanense

mycolabadmin

Researchers identified a new species of Trichoderma fungus that causes green mold disease in cultivated medicinal mushrooms, particularly Ganoderma sichuanense. Using DNA analysis and genetic comparison, they showed that this new species belongs to a group of Trichoderma fungi that are close relatives of species used for controlling plant diseases. The study suggests this fungus might have potential as a biocontrol agent while currently being problematic for mushroom farmers in China.

Study of the antagonistic relationship between gene expression biofilm of Aspergillus niger and Staphylococcus aureus that cause otomycosis

mycolabadmin

Researchers studied how bacteria (S. aureus) and fungi (A. niger) interact when both infect the ear canal, a condition called otomycosis. They found that bacteria significantly suppress the fungus’s ability to form protective biofilms by reducing the expression of genes needed for fungal growth. This antagonistic relationship suggests that mixed infections might actually be easier to treat than pure fungal infections, offering new insights for managing ear infections.

Superhydrophobic Fatty Acid-Based Spray Coatings with Dual-Mode Antifungal Activity

mycolabadmin

Scientists developed easy-to-apply spray coatings made from natural fatty acids that repel water and kill fungal infections like gray mold. By combining long-chain fatty acids with shorter fatty acids like those found in food preservatives, the coatings can either passively prevent fungus from sticking to surfaces or actively kill it. These coatings are environmentally friendly, sustainable alternatives to chemical fungicides that fungi are becoming resistant to, and could be used to protect everything from building surfaces to stored crops.

Case Commentary: Successful use of olorofim for the treatment of multi-drug-resistant Lomentospora prolificans infection in a child

mycolabadmin

A young girl contracted a dangerous drug-resistant fungal infection in her knee after an injury, which failed to respond to standard antifungal treatments. Doctors obtained special access to an experimental antifungal drug called olorofim through a compassionate use program. The child showed improvement within two weeks and was completely cured after six months of treatment with no signs of the infection returning two years later, making this the first successful case of this new drug being used in a child.

Conversion of Soluble Compounds in Distillery Wastewater into Fungal Biomass and Metabolites Using Australian Ganoderma Isolates

mycolabadmin

Researchers discovered that Ganoderma mushroom mycelium can clean up rum distillery wastewater while producing edible, protein-rich fungal biomass. The mycelium successfully removed harmful compounds from the wastewater and accumulated bioactive compounds with health benefits. This dual-benefit approach transforms an environmental waste problem into a valuable food ingredient, offering a sustainable and economical solution for the distillery industry.

Microbe Profile: Streptomyces formicae KY5: an ANT-ibiotic factory

mycolabadmin

Scientists have discovered a special bacterium called Streptomyces formicae that lives with ants in African acacia trees and produces powerful antibiotics. This bacterium naturally makes compounds called formicamycins that can kill dangerous antibiotic-resistant bacteria like MRSA, as well as antifungal compounds. Researchers are using advanced gene-editing techniques to unlock more hidden antimicrobial compounds from this bacterium’s genome, which could lead to discovering new medicines to treat infections.

Caspofungin therapy in prosthetic valve endocarditis and candidemia due to itraconazole-resistant Candida glabrata (Nakaseomyces glabratus): A case report

mycolabadmin

A 13-year-old boy developed a serious fungal infection of his heart valve after surgery. The infection was caused by a resistant yeast that didn’t respond to initial antifungal treatment. Doctors used molecular testing to identify the exact fungal species and tested how it responded to different medications. After switching to a different antifungal drug called caspofungin, the patient recovered completely and remained healthy.

Acute effects of psilocybin on attention and executive functioning in healthy volunteers: a systematic review and multilevel meta-analysis

mycolabadmin

This comprehensive review examined how psilocybin affects thinking and attention. Researchers analyzed 13 studies and found that psilocybin slows down reaction times during tasks requiring focus and decision-making, though accuracy remains relatively stable. The effects increase with higher doses. Understanding these cognitive changes is important for both therapeutic applications and ensuring safe use of psilocybin in research and clinical settings.

Research Topic: Medicinal